A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final analysis in Western patients was not enough to be statistically significant — a shortfall that could keep the blockbuster hopeful from securing U.S. and European regulatory approvals.

The results are important because they’re the first Phase 3 data for an emerging class of drugs, bispecific antibodies designed to block two targets, PD-1 and VEGF. The results are also notable because ivonescimab thrust itself into the spotlight a year ago with data topping Merck’s juggernaut Keytruda, a monoclonal antibody that blocks PD-1, in a head-to-head study . Ivonescimab’s dual approach could help patients w

See Full Page